Development Programs
The company’s lead candidate, HspE7, is a novel therapeutic vaccine intended for the treatment of HPV-related diseases. HspE7 is derived from Nventa’s patented CoVal fusion platform that uses recombinant DNA technology to covalently fuse heat shock proteins to target antigens, thereby stimulating cellular immune system responses to specific diseases. Nventa is developing HspE7 in combination with the Toll-like receptor 3 (TLR3) agonist adjuvant Poly-ICLC for multiple indications, including Cervical Intraepithelial Neoplasia (also known as cervical dysplasia or CIN), Genital Warts, Cervical Cancer, and head and neck cancers.
According to the annual information form, for the year ending December 31, 2009, provided on Akela Pharma's website, scientific research funding has ceased for HspE7.
Nventa is also developing two additional therapeutic vaccine programs based on its CoVal technology—a Hsp – HBV (hepatitis B) fusion, and prototypes of Hsp fusion proteins with influenza antigens.
In June 2008, Nventa announced the development of a proprietary vaccine adjuvant, Poly IC – Poly Arginine (Poly-ICR), for use with both therapeutic and prophylactic vaccines. Poly-ICR is a TLR3 agonist that, when combined with a disease-specific antigen, can induce both cytotoxic (T cell) and antibody (B cell) immune responses against that antigen. As yet unpublished pre-clinical data indicate that Poly-ICR, in combination with a tumor-associated antigen, increases antigen-specific CD8 T-cell levels, while both inducing regression of tumors and preventing tumor growth in mouse models. The company developed Poly-ICR for both internal use and for external licensing opportunities.
Read more about this topic: Nventa Biopharmaceuticals Corporation
Famous quotes containing the words development and/or programs:
“As long as fathers rule but do not nurture, as long as mothers nurture but do not rule, the conditions favoring the development of father-daughter incest will prevail.”
—Judith Lewis Herman (b. 1942)
“Although good early childhood programs can benefit all children, they are not a quick fix for all of society’s ills—from crime in the streets to adolescent pregnancy, from school failure to unemployment. We must emphasize that good quality early childhood programs can help change the social and educational outcomes for many children, but they are not a panacea; they cannot ameliorate the effects of all harmful social and psychological environments.”
—Barbara Bowman (20th century)